The government has tried to harness profit-driven drugmaking to serve public health before. The results were underwhelming.
Rigor académico, oficio periodístico
Artículos sobre Purdue Pharma
Mostrando todos artículos
The government has tried to harness a profit-driven drug industry to serve public health before.
While critics accuse companies facing lots of lawsuits of using bankruptcy as a sort of 'get of jail free card,' the reality of the legal procedure is more complicated.
A policy response focused on reducing prescription opioids will not resolve North America's opioid crisis. And it is hurting many adults who live with otherwise unbearable chronic pain.
The $270 million settlement may not mean a whole lot if Purdue files for bankruptcy as it's reportedly considering.
There are limits to what charities can do now about past donors who are accused of morally reprehensible behavior.
OxyContin maker Purdue has reportedly been mulling a bankruptcy filling, just as the first of around 2,000 lawsuits against it prepares to go to trial.
The interests of pharmaceutical companies and public health are not the same. Industry dollars can distort research agendas, while framing health challenges and solutions in ways that benefit corporations.
Considered in historical context, Purdue's plan to peddle opioid addiction medicines to vulnerable people is not so surprising. Gilded-Age pharmaceutical companies used similar strategies.
Principales colaboradores
-
Associate Professor of History, University at Buffalo
-
Director of the Bioethics Program and affiliate faculty in Law and International Affairs, Penn State
-
Professor of Law, Texas A&M University
-
Postdoctoral Scholar, Penn State
-
Associate Professor, School of Physical Therapy, Western University
-
Assistant Professor of Law, University of Georgia
-
Professor of Law, Case Western Reserve University
-
Professor of Law, IUPUI
